Lisa L Hall-Anderson

Lisa L Hall-Anderson is an Associate Professor at UMass Chan Medical School, holding positions in the Department of Neurology at the T.H. Chan School of Medicine, the NeuroNexus Institute, and the Neuroscience Department at the Morningside Graduate School of Biomedical Sciences. She has been collaborating with Dr. Jeanne Lawrence in the Department of Neurology since 1999, focusing on fundamental questions about genome regulation and their clinical implications in epigenetics.

Her educational background includes:

• BA in Biology from Colorado College, Colorado Springs, CO
• PhD in Genetics from University of California, Davis, CA

Dr. Hall-Anderson's research centers on the functional organization of the nucleus and its role in gene expression during differentiation and disease. Her primary research interests include:

• How long non-coding RNAs interact with chromatin
• The functional importance of the repeat genome in gene regulation and nuclear structure
• Epigenetic mechanisms of X-chromosome inactivation
• Developing novel gene therapy approaches for Down syndrome by silencing the extra chromosome 21

Her publication record demonstrates a consistent focus on nuclear architecture, noncoding RNA biology, and epigenetic regulation. Recent work has particularly emphasized the role of repetitive DNA elements in chromosome organization and the therapeutic potential of XIST RNA for trisomy 21 correction. Her research bridges fundamental chromosome biology with translational applications, especially in the context of Down syndrome.

As a key member of Dr. Jeanne Lawrence's laboratory, Dr. Hall-Anderson has contributed significantly to establishing XIST RNA as the first long non-coding RNA that "paints" the entire inactive X-chromosome. Her work has helped pioneer the understanding of how non-coding RNA can control whole-chromosome regulation, with implications for both basic science and clinical applications in chromosome disorders.

Dr. Hall-Anderson's laboratory work involves molecular cytology approaches, transgenics, bioinformatics, and cytological epigenetics to study how XIST RNA interacts with chromosomes. Since 2007, she has been involved in an ambitious project translating chromosome biology discoveries into a novel approach for correcting trisomy 21 in Down syndrome, demonstrating that the XIST gene can be targeted into extra chromosome 21 in patient-derived cells to repress transcription.